万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
2-8℃
- 保质期:
见包装
- 英文名:
Oridonin
- 库存:
大量现货
- 供应商:
上海研谨生物
- CAS号:
28957-04-2
- 规格:
20mg
冬凌草甲素
分析标准品,HPLC≥98%
Oridonin
CAS号:28957-04-2
分子式:C20H28O6
分子量:364.43
MDL:MFCD00221762
|
货号 |
规格/参数/品牌 |
价格 |
货期 |
|
YJ-B20310-20mg |
分析标准品,HPLC≥98% |
¥350.00 |
现货 |
|
JS28299-100mg |
98% |
¥600.00 |
现货 |
|
JS28299-1g |
98% |
¥2150.00 |
现货 |
|
JS28299-5g |
98% |
¥6200.00 |
现货 |
|
A10325-20mg |
分析标准品,含量94.8%,可溯源 |
¥1600.00 |
现货 |
产品介绍
Oridonin是从Rabdosia rubescens中得到的二萜,是一种AKT抑制剂,对 AKT1 和 AKT2 的IC50值分别为 8.4 和 8.9 μM,具有抗菌、抗炎、抗肿瘤等功效。
熔点:248-250℃
沸点:599.8℃ at 760 mmHg
比旋光度:(c, 0.1 in EtOH)-47
外观:淡黄色针状结晶
溶解性:DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic)
储存条件:2-8℃
注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验参考文献(46篇)
46. [IF=6.8] Kong Jiahui et al."Biomimetic MOFs Nanoparticles Co-Delivering Oridonin and siRNA for Synergistic Therapy in Melanoma via ferroptosis pathway."Journal of Science-Advanced Materials and Devices.2025 Jul;:100957
45. [IF=5.4] Junli Zhang et al."Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer."ACS Biomaterials Science & Engineering.2025;XXXX(XXX):XXX-XXX
44. [IF=3] Jushuang Li et al."Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway."RENAL FAILURE.
43. [IF=6] Mengting Li et al."Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury."EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2024 Aug;:116760
42. [IF=1.8] Gengzhen Huang et al."Oridonin attenuates diabetes‑induced renal fibrosis via the inhibition of TXNIP/NLRP3 and NF‑κB pathways by activating PPARγ in rats."EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES".2024 May;0:
41. [IF=14.5] Mengru Cai et al."An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy."Acta Pharmaceutica Sinica B".2024 May;:
40. [IF=4.6] Tianming Lu et al."Inhibition of ALDOA and ENO1-mediated Glycolysis of Oridonin as a Novel Anti-tumor Strategy of Non-small Cell Lung Cancer."Advanced Therapeutics".2024 Apr;:2400027
39. [IF=5] Shiying Ye et al."Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1."EUROPEAN JOURNAL OF PHARMACOLOGY".2024 Apr;:176620
38. [IF=3.8] Zhang Feifan et al."Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells."BMC CANCER".2024 Dec;24(1):1-11
37. [IF=4.5] Lunji Wang et al."Antibacterial Mechanisms and Antivirulence Activities of Oridonin against Pathogenic Aeromonas hydrophila AS 1.1801."Microorganisms".2024 Feb;12(2):415
36. [IF=9.965] Mengru Cai et al."Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin."JOURNAL OF COLLOID AND INTERFACE SCIENCE.2023 Apr;:
35. [IF=2.602] ZHOU Wei et al."Preparation and characterization of an oridonin and γ-cyclodextrin complex."Food Science and Technology.2022 Aug;42:
34. [IF=5.811]
33. [IF=2.248] Yang Huiyu et al."Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells."Anti-Cancer Drug. 2022 Jan;33(1):e444-e452
32. [IF=2.447] Yun Gui et al."Oridonin improves the therapeutic effect of lentinan on lung cancer."Exp Ther Med. 2021 Aug;22(2):1-9
31. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950
30. [IF=3.361] Mengru Cai et al."Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior."Rsc Adv. 2020 Oct;10(60):36862-36872
29. [IF=3.503] Lili Tian et al."Preliminary safety assessment of oridonin in zebrafish."Pharm Biol. 2019;57(1):632-640
28. [IF=3.591] Mengru Cai et al."Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers."New J Chem. 2020 Oct;44(41):17693-17704
27. [IF=6.543] Hong Mu-keng et al."Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury."Oxid Med Cell Longev. 2021;2021:3259238
26. [IF=0] Gan Zhao et al."Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury."Oncotarget. 2017 Sep 15; 8(40): 68153–68164
25. [IF=1.785] Tao Xu et al."Oridonin enhances in vitro anticancer effects of lentinan in SMMC‑7721 human hepatoma cells through apoptotic genes."Exp Ther Med. 2017 Nov;14(5):5129-5134
24. [IF=2.833] Tian Lili et al."Antiangiogenic effects of oridonin."Bmc Complem Altern M. 2017 Dec;17(1):1-15
23. [IF=3.361] Jushuang Li et al."Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways."Int Immunopharmacol. 2018 Feb;55:9
22. [IF=3.571] Xiangling Xiao et al."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways."Int J Oncol. 2016 Jun;48(6):2608-2618
21. [IF=3.723] Yang Sun et al."Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma."Chem-Biol Interact. 2018 Dec;296:57
20. [IF=5.722] Liu Qian-Qian et al."Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway."Cancer Cell Int. 2016 Dec;16(1):1-8
19. [IF=5.959] Lu Ying et al."Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway."Cell Death Dis. 2018 Jan;9(1):1-16
18. Tian, L., Xie, K., Sheng, D. et al. Antiangiogenic effects of oridonin. BMC Complement Altern Med 17, 192 (2017). https:##doi.org/10.1186/s12906-017-1706-3
17. Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164. Published 2017 Jul 12. doi:10.18632/oncotarget.19249
16. Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., Liu, Y."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways". International Journal of Onco
15. Yang Sun, Xiubo Jiang, Ying Lu, Jianwei Zhu, Lisha Yu, Bo Ma, Qi Zhang, Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma, Chemico-Biological Interactions,
14. Jushuang Li, Liping Bao, Dongqing Zha, Lian Zhang, Ping Gao, Juan Zhang, Xiaoyan Wu, Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, International Immunopharmaco
13. Cai, Mengru, et al. "Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers." New Journal of Chemistry 44.41 (2020): 17693-17704.DOI https:##doi.org/10.1039/D0NJ03680C
12. 王倩,纠敏,孟媛媛,孔铭杰,殷成芮,汪伦记.冬凌草甲素/壳聚糖复合膜对冰鲜鸡胸肉的保鲜效果[J].食品与机械,2021,37(03):125-130.
11. 李峥, 王强, 张晓莉. 蓝萼香茶菜提取溶剂的选择及其耐缺氧作用研究[J]. 中华中医药学刊, 2012, 030(006):1375-1377.
10. 何中维 肖香玲 蔡芬 张亮 黄秋月 段超 刘莹.冬凌草甲素逆转人胃癌细胞SGC 7901/DDP顺铂耐药的作用及机制研究[J].湖北医药学院学报 2016 35(03):261-265+226.
9. 尚曙玉 张铁山 郝海军 等. 冬凌草甲素磷脂复合物不同制剂在SD大鼠体内生物利用度的比较[J]. 中药材 2019 v.42;No.422(04):170-173.
8. 杜利月 郭留城 郝海军 等. 冬凌草甲素渗透泵片制备工艺研究及体外评价[J]. 中药材 2018 v.41;No.407(01):173-176.
7. 田丽莉 盛东来 朱国福. 冬凌草甲素抑制血管生成活性及作用机制[J]. 中国实验方剂学杂志 2016 022(005):166-171.
6. 纠敏 闫鹏 闫国庆 等. 冬凌草甲素对金黄色#葡萄*球菌的抑菌作用机制[J]. 江苏农业科学 2019 47(07):202-206.
5. 纠敏 闫鹏 李晶晶 等. 冬凌草甲素对金黄色#葡萄*球菌生物膜的抑制机制[J]. 微生物学通报 2020 v.47(05):250-256.
4. 田丽莉 朱国福 盛东来. 冬凌草甲素对人脐静脉内皮细胞的抑制作用[J]. 温州医学院学报 2017 047(012):880-883 887.
3. 肖香玲 何中维 黄秋月 季娟丽 张云飞 刘莹.冬凌草甲素下调EGFR/ERK/MMP-12和CIP2A/Akt信号通路抑制gefitinib耐受的非小细胞肺癌的转移[J].湖北医药学院学报 2016 35(06):536-542+629.
2. 纠敏 孟媛媛 王倩 等. 冬凌草甲素/壳聚糖复合膜的性能和结构表征[J]. 食品与发酵工业 2019 045(024):119-123.
1. 汪伦记 许美秋 纠敏 等. 冬凌草提取物对金黄色#葡萄*球菌生物膜形成的抑制作用[J]. 天然产物研究与开发 2017 029(006):1000-1005.
下的死体积应尽可能的小,如果支掌滤板下的死体积大,被分离组分之间重新混合的可能性就大,其结果是影响洗脱峰形,出现拖尾出象,降低分辩力。在精确分离时,死体积不能超过总床体积的1/1000。 以中压柱层析 法提取分离冬凌草甲素为例 中压分离层析柱 操作方法 以中压柱层析法提取分离冬凌草甲素为例 1 吸附剂的处理及柱子装填 将一定量薄层层析硅胶装人搪瓷盘置于烘箱中,于105。C活化2H后,取出放置室温即可装柱。柱子采用干法填充,填满整个柱体
技术资料暂无技术资料 索取技术资料









